Literature DB >> 32515984

Endothelial HIF-2α as a Key Endogenous Mediator Preventing Emphysema.

Shravani Pasupneti1,2, Wen Tian1,2, Allen B Tu1,2, Petra Dahms1,2, Eric Granucci1,2, Aneta Gandjeva3, Menglan Xiang1,2, Eugene C Butcher1,2, Gregg L Semenza4,5,6,7,8,9,10,11, Rubin M Tuder3, Xinguo Jiang1,2, Mark R Nicolls1,2.   

Abstract

Rationale: Endothelial injury may provoke emphysema, but molecular pathways of disease development require further discernment. Emphysematous lungs exhibit decreased expression of HIF-2α (hypoxia-inducible factor-2α)-regulated genes, and tobacco smoke decreases pulmonary HIF-2α concentrations. These findings suggest that decreased HIF-2α expression is important in the development of emphysema.
Objectives: The objective of this study was to evaluate the roles of endothelial-cell (EC) HIF-2α in the pathogenesis of emphysema in mice.
Methods: Mouse lungs were examined for emphysema after either the loss or the overexpression of EC Hif-2α. In addition, SU5416, a VEGFR2 inhibitor, was used to induce emphysema. Lungs were evaluated for HGF (hepatocyte growth factor), a protein involved in alveolar development and homeostasis. Lungs from patients with emphysema were measured for endothelial HIF-2α expression.Measurements and Main
Results: EC Hif-2α deletion resulted in emphysema in association with fewer ECs and pericytes. After SU5416 exposure, EC Hif-2α-knockout mice developed more severe emphysema, whereas EC Hif-2α-overexpressing mice were protected. EC Hif-2α-knockout mice demonstrated lower levels of HGF. Human emphysema lung samples exhibited reduced EC HIF-2α expression.Conclusions: Here, we demonstrate a unique protective role for pulmonary endothelial HIF-2α and how decreased expression of this endogenous factor causes emphysema; its pivotal protective function is suggested by its ability to overcome VEGF antagonism. HIF-2α may maintain alveolar architecture by promoting vascular survival and associated HGF production. In summary, HIF-2α may be a key endogenous factor that prevents the development of emphysema, and its upregulation has the potential to foster lung health in at-risk patients.

Entities:  

Keywords:  emphysema; hepatocyte growth factor; hypoxia-inducible factor-2α

Mesh:

Substances:

Year:  2020        PMID: 32515984      PMCID: PMC7528783          DOI: 10.1164/rccm.202001-0078OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   30.528


  61 in total

1.  An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure.

Authors:  Connie C W Hsia; Dallas M Hyde; Matthias Ochs; Ewald R Weibel
Journal:  Am J Respir Crit Care Med       Date:  2010-02-15       Impact factor: 21.405

Review 2.  Pharmacologic Targeting of Hypoxia-Inducible Factors.

Authors:  Gregg L Semenza
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

3.  Hepatocyte growth factor is required for alveologenesis in the neonatal rat.

Authors:  Sanna Padela; Judy Cabacungan; Samuel Shek; Rosetta Belcastro; Man Yi; Robert P Jankov; A Keith Tanswell
Journal:  Am J Respir Crit Care Med       Date:  2005-06-30       Impact factor: 21.405

4.  Vanishing vessels aboding pulmonary disease: a role for VEGFR2.

Authors:  Liza Botros; Anton Vonk Noordegraaf; Jurjan Aman
Journal:  Eur Respir J       Date:  2020-04-03       Impact factor: 16.671

5.  Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.

Authors:  Jennifer L Ariazi; Kevin J Duffy; David F Adams; Duke M Fitch; Lusong Luo; Melissa Pappalardi; Mangatt Biju; Erin Hugger DiFilippo; Tony Shaw; Ken Wiggall; Connie Erickson-Miller
Journal:  J Pharmacol Exp Ther       Date:  2017-09-19       Impact factor: 4.030

6.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.

Authors:  H Tian; S L McKnight; D W Russell
Journal:  Genes Dev       Date:  1997-01-01       Impact factor: 11.361

7.  Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha.

Authors:  M S Wiesener; H Turley; W E Allen; C Willam; K U Eckardt; K L Talks; S M Wood; K C Gatter; A L Harris; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

8.  Hypoxia-inducible transcription factors, HIF1A and HIF2A, increase in aging mucosal tissues.

Authors:  Jeffrey L Ebersole; Michael John Novak; Luis Orraca; Janis Martinez-Gonzalez; Sreenatha Kirakodu; Kuey C Chen; Arnold Stromberg; Octavio A Gonzalez
Journal:  Immunology       Date:  2018-02-14       Impact factor: 7.397

9.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.

Authors:  G L Wang; B H Jiang; E A Rue; G L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  A Single-Cell Transcriptional Roadmap of the Mouse and Human Lymph Node Lymphatic Vasculature.

Authors:  Menglan Xiang; Rubén Adrián Grosso; Akira Takeda; Junliang Pan; Tove Bekkhus; Kevin Brulois; Denis Dermadi; Sofia Nordling; Michael Vanlandewijck; Sirpa Jalkanen; Maria H Ulvmar; Eugene C Butcher
Journal:  Front Cardiovasc Med       Date:  2020-04-30
View more
  9 in total

1.  Cigarette smoke-induced airspace disease in mice develops independently of HIF-1α signaling in leukocytes.

Authors:  Patrick S Hume; Jazalle McClendon; Katrina W Kopf; Julie W Harral; Joanna M Poczobutt; Alexandra L McCubbrey; Bradford J Smith; Peter M Henson; Susan M Majka; Irina Petrache; William J Janssen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-08-09       Impact factor: 6.011

2.  Exploring disease interrelationships in patients with lymphatic disorders: A single center retrospective experience.

Authors:  Stanley G Rockson; Xin Zhou; Lan Zhao; Davood K Hosseini; Xinguo Jiang; Andrew J Sweatt; Dongeon Kim; Wen Tian; Michael P Snyder; Mark R Nicolls
Journal:  Clin Transl Med       Date:  2022-04

3.  Decreased lymphatic HIF-2α accentuates lymphatic remodeling in lymphedema.

Authors:  Xinguo Jiang; Wen Tian; Eric J Granucci; Allen B Tu; Dongeon Kim; Petra Dahms; Shravani Pasupneti; Gongyong Peng; Yesl Kim; Amber H Lim; F Hernan Espinoza; Matthew Cribb; J Brandon Dixon; Stanley G Rockson; Gregg L Semenza; Mark R Nicolls
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

4.  Update in Chronic Obstructive Pulmonary Disease 2020.

Authors:  Andy I Ritchie; Jonathon R Baker; Trisha M Parekh; James P Allinson; Surya P Bhatt; Louise E Donnelly; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

Review 5.  Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury.

Authors:  Xiangyun Li; Nathanial K Berg; Tingting Mills; Kaiying Zhang; Holger K Eltzschig; Xiaoyi Yuan
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

Review 6.  Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.

Authors:  Stanislav Kotlyarov; Aleksei Bulgakov
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

Review 7.  Hypoxia and Hypoxia-Inducible Factors in Lymphedema.

Authors:  Xinguo Jiang; Wen Tian; Dongeon Kim; Alexander S McQuiston; Ryan Vinh; Stanley G Rockson; Gregg L Semenza; Mark R Nicolls
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.988

8.  Erythropoietin in bone homeostasis-Implications for efficacious anemia therapy.

Authors:  Katrina M Lappin; Ken I Mills; Terence R Lappin
Journal:  Stem Cells Transl Med       Date:  2021-01-21       Impact factor: 6.940

Review 9.  Hypoxia-Inducible Factor Signaling in Inflammatory Lung Injury and Repair.

Authors:  Colin E Evans
Journal:  Cells       Date:  2022-01-06       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.